KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
EBRT Plus Focal Boost Sustains Biochemical DFS Benefit in Prostate Cancer
The 10-year biochemical DFS rate was 86% with EBRT plus focal boost vs 71% with standard EBRT in those with intermediate- and high-risk prostate cancer.
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Navigating Dramatic Changes and Using Novel Therapies in CLL Management
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
FDA Grants FTD to WTX-124 in Advanced Pretreated Cutaneous Melanoma
Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.
How Does One Manage Talquetamab’s Unique AE Profile in Multiple Myeloma?
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Tackling Logistical and Socioeconomic Challenges in Blood Cancer Care
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
How Can Caregivers Find Support During Oncology Treatment?
Kelly Dyckman, MSW, LCSW, offers advice for caregivers of patients with cancer, emphasizing the need for proactive self-care and recognizing burnout.
Collaborating to Overcome Barriers to Novel Hematologic Cancer Therapies
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.
Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer
Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.
Tumor Size Determines Treatment Modality in Uveal Melanoma
Brachytherapy plaque with vitrectomy and silicone oil was most often given to patients with uveal melanoma tumors sized 2 mm or larger.
Japan’s MHLW Receives sNDA For T-DXd Combo in Frontline HER2+ Breast Cancer
Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.
Forming Collaborations With The Physical Therapy Team in Cancer Treatment
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Proactive Psychosocial Support May Improve Mental Health in Oncology Care
Kelly Dyckman, MSW, LCSW, discusses the need for proactive, not reactive, communication about posttreatment challenges to better support cancer survivors.
Managing BCMA/GPRC5D-Associated CRS and ICANS in the Real-World Setting
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Adjuvant Endocrine/Radiation Therapy May Limit Breast Cancer Recurrence
Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.
Giving Psychosocial Support for Sexual Health Issues in Cancer Care
Recommending counseling sessions may help patients with cancer navigate sexual health and emotional issues during their cancer treatment.
Uveal Melanoma Study Shows High Efficacy Rates After RT/Vitrectomy Regimen
Tara A. McCannel, MD, PhD, discusses how brachytherapy plaque with vitrectomy and silicone oil led to a 100% survival rate in patients with uveal melanoma.
The Essential Role of Clinical Social Work in Oncology
Kelly Dyckman, MSW, LCSW, discusses how her role integrates with multidisciplinary oncology teams to support patients' emotional and relational well-being.
FDA Grants Priority Review to BLA for Orca-T in Hematologic Malignancies
The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.
Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma
Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.
Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials
Data support the intravesical mitomycin solution’s role as an innovative option for those with recurrent, low-grade, intermediate-risk NMIBC.
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
The safety profile of dato-DXd was consistent with previous clinical trials assessing the agent in breast cancer.
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
Casdatifan, administered at 100 mg once daily, achieved a confirmed ORR of 35% in patients with pretreated metastatic kidney cancer.
Who Should Receive RT Plus Vitrectomy/Silicone Oil in Uveal Melanoma?
Patients with uveal melanoma who have tumors larger than 2 mm are candidates for brachytherapy plaque with vitrectomy and silicone oil.
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
RLT-based combinations, RLTs across genitourinary cancers, and RLTs in earlier lines of therapy are among the considerations for further research.
